A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions
  • Acronyms MAVERICK-HCM
  • Sponsors MyoKardia
  • Most Recent Events

    • 02 Apr 2018 According to a MyoKardia media release, Dr. Stephen Heitner, cardiologist at the Oregon Health & Science University Knight Cardiovascular Institute is the principal investigator for this trial.
    • 02 Apr 2018 According to a MyoKardia media release, first patient has been dosed, and topline are anticipated in the second half of 2019.
    • 02 Apr 2018 Status changed from not yet recruiting to recruiting, according to a MyoKardia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top